They are considered ineffective against the variants currently in circulation.

Experts from the World Health Organization (WHO) "strongly recommend" no longer using two anti-Covid treatments with synthetic antibodies.

These are xevudy, based on the sotrovimab molecule, and ronapreve, based on the casirivimab-imdevimab combination.

These recommendations were published in the latest version of their guide to anti-Covid treatments, published overnight from Thursday to Friday in the

British Medical Journal

.

Challenged with the arrival of Omicron

Xevudy, developed by the GSK and Vir laboratories, and Ronapreve, developed by Regeneron, are two synthetic antibody treatments against Covid.

Until then, the WHO recommended, with caution, their use in patients with a mild form of the disease, but at risk of progression to a more serious form, due to their age, weight or other factors.

However, the arrival of the Omicron variant at the end of 2021 called into question the interest of these treatments and WHO experts, on the basis of several

in vitro

studies , now believe that they are probably ineffective against the strains in circulation. .

At the same time, the experts updated recommendations on other treatments, in particular remdesivir from the Gilead laboratory.

This, recommended until then in the event of a mild form of Covid, can, in the light of new studies, be considered in certain serious cases, according to the experts.

However, in so-called “critical” cases, the studies do not show a benefit from remdesivir and the experts therefore advise against its use.

Health

Covid-19: Size of the drops, humidity… We now know more about the conditions at risk of transmission of the virus

Health

Covid-19: Contaminations, incidence rate... Is France on the verge of an eighth wave?

  • Health

  • Covid-19

  • Coronavirus

  • Treatment

  • WHO

  • epidemic